UBS AM’s Claritev CTEV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.46K Buy
+116
New +$3.65K ﹤0.01% 4012
2024
Q3
– Sell
-12,774
Closed -$198K – 2874
2024
Q2
$198K Buy
12,774
+7,219
+130% +$172K ﹤0.01% 2755
2024
Q1
$180K Hold
5,555
– – ﹤0.01% 2476
2023
Q4
$320K Hold
5,555
– – ﹤0.01% 2413
2023
Q3
$373K Hold
5,555
– – ﹤0.01% 2380
2023
Q2
$236K Hold
5,555
– – ﹤0.01% 2536
2023
Q1
$236K Hold
5,555
– – ﹤0.01% 2536
2022
Q4
$256K Hold
5,555
– – ﹤0.01% 2377
2022
Q3
$636K Sell
5,555
-1,406
-20% -$233K ﹤0.01% 2230
2022
Q2
$1.53M Buy
6,961
+681
+11% +$135K ﹤0.01% 1743
2022
Q1
$1.18M Buy
6,280
+1,890
+43% +$311K ﹤0.01% 2054
2021
Q4
$778K Buy
4,390
+1,505
+52% +$268K ﹤0.01% 2348
2021
Q3
$650K Hold
2,885
– – ﹤0.01% 2382
2021
Q2
$1.1M Buy
+2,885
New +$894K ﹤0.01% 2150

Other funds holding CTEV

UBS AM's CTEV Position: Q3 2026 in Review

UBS AM opened a new position in Claritev (CTEV) in Q3 2026: 116 shares worth $2.46K. The stake represents ﹤0.01% of the portfolio and ranks #4012 among its holdings. This is a return to the name: UBS AM previously reported a position in CTEV as recently as Q2 2024.

UBS AM first reported a position in CTEV in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.53M in Q2 2022. 87 funds tracked by Wall St. Rank hold CTEV as of Q3 2026.

  • UBS AM held 116 shares of Claritev worth $2.46K as of Q3 2026.
  • Claritev was a new UBS AM position in Q3 2026.
  • Claritev made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4012 holding.
  • UBS AM first reported a position in Claritev in Q2 2021 and has held it in 14 quarters since.
  • UBS AM's Claritev position peaked at $1.53M in Q2 2022.
  • 87 funds tracked by Wall St. Rank held Claritev as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.